New cancer drug combo enters human testing
NCT ID NCT05162755
Summary
This early-stage trial is testing a new cancer drug called S095029, both alone and combined with an existing immunotherapy drug (Sym021). The study aims to find safe doses and see if these treatments show early signs of fighting advanced solid tumors in patients who have run out of standard treatment options. The trial will not proceed to testing triple-drug combinations as originally planned.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Princess Margaret Cancer Centre
Toronto, Canada
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
The START Center for Cancer Care
San Antonio, Texas, 78229, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.